Piper Sandler Maintains Overweight on Bioage Labs, Lowers Price Target to $40
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Yasmeen Rahimi maintains Bioage Labs (NASDAQ:BIOA) with a Overweight and lowers the price target from $73 to $40.
Piper Sandler analyst Yasmeen Rahimi maintains Bioage Labs (NASDAQ:BIOA) with a Overweight and lowers the price target from $73 to $40.